Ligand Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
to $240 million and adjusted EPS to $8.13 (up 42%), while ending the year with $734 million in cash and “over $1 billion” in deployable capital. Key product drivers: Royalty revenue rose 48% to $161 million, powered by blockbuster momentum in FILSPARI (U.S. Q4 sales $103M, Ligand royalties ~$32M on $355M global sales), strong sales of CAPVAXIVE and Ohtuvayre , and solid performance from QARZIBA 2026 outlook reiterated: Management reaffirmed guidance of ~ $8–9 adjusted EPS and $200–225M royalty revenue (total revenue $245–285M), noting continued royalty growth from FILSPARI, Ohtuvayre, CAPVAXIVE and ZELSUVMI and plans to accelerate business development and royalty financing activity. Interested in Ligand Pharmaceuticals Incorporated? Here are five stocks we like better. Ligand Pharmaceuticals (NASDAQ:LGND) reported what management described as a “defining” and “breakout” year in 2025, driven by growth across its royalty portfolio and what it called a lean operating model. On th
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand Pharmaceuticals (LGND) had its price target raised by Oppenheimer Holdings, Inc. from $275.00 to $277.00. They now have an "outperform" rating on the stock.MarketBeat
- Ligand Pharma (LGND) Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Ligand: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Ligand Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Ligand Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
LGND
Earnings
- 2/26/26 - Beat
LGND
Sec Filings
- 2/26/26 - Form 8-K
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- LGND's page on the SEC website